Exai Bio Inc.
Palo Alto, US · Founded 2021 · 1 known investors
ExAI develops technology for early cancer detection, diagnosis, and management. The company serves healthcare providers and patients in the oncology space.
Founders & leadership
AP
Alexander ParkerNamed on SEC filing
HG
Hani GoodarziNamed on SEC filing
MP
Michael PelliniNamed on SEC filing
PA
Patrick A. ArensdorfNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$70.6MraisedOct 2022 · 21 investors · BiotechnologyRule 506(b)
▶$70.6MraisedOct 2022 · 21 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Alexander ParkerDirector
- Hani GoodarziDirector
- Michael PelliniDirector
- Patrick A. ArensdorfExecutive Officer, Director
- Offering amount
- $71.5M
- Amount sold
- $70.6M
- First sale
- Sep 2021
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Exai Bio Inc. do?
- ExAI develops technology for early cancer detection, diagnosis, and management. The company serves healthcare providers and patients in the oncology space.
- Who are Exai Bio Inc.'s investors?
- Exai Bio Inc.'s investors include Amplify Partners.
- Where is Exai Bio Inc. headquartered?
- Exai Bio Inc. is headquartered in Palo Alto, US.